<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624490</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00146119</org_study_id>
    <nct_id>NCT04624490</nct_id>
  </id_info>
  <brief_title>Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease</brief_title>
  <official_title>Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Castro, MD, MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP)&#xD;
      129Xe gas MRI for regional assessment of pulmonary function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an unblinded, open-label study with ~160 subjects with diagnosed pulmonary disease&#xD;
      and ~100 healthy controls. Subjects to be enrolled will include males and females 18-80 years&#xD;
      old. Evaluation will be on an outpatient basis. Imaging will be done on a single day and will&#xD;
      involve administration of up to four 1-liter doses of HP 129Xe plus one 129Xe calibration&#xD;
      dose (~300-400mL HP 129Xe). In addition to 129Xe MRI, a series of anatomical conventional 1H&#xD;
      MR images will be collected including a localizer scan, breath-hold spin echo image, and&#xD;
      breath-hold steady-state free precession image to highlight the vasculature. All subjects&#xD;
      will be evaluated at one center: The University of Kansas Medical Center, KS USA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">October 26, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 26, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RBC/Barrier Ratio</measure>
    <time_frame>Day 1</time_frame>
    <description>Ratio of xenon signal dissolved in RBCs to xenon signal dissolved in Barrier Tissues</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADC</measure>
    <time_frame>Day 1</time_frame>
    <description>Apparent Diffusion Coefficient of Xenon Gas in the lungs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation Defect Percentage</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of the Lungs with ventilation signal below a threshold level</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Asthma</condition>
  <condition>COPD</condition>
  <condition>Interstitial Lung Disease</condition>
  <condition>Cystic Fibrosis</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>Pulmonary Infection</condition>
  <condition>Other Lung Disease</condition>
  <arm_group>
    <arm_group_label>Hyperpolarized 129Xe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of hyperpolarized xenon during MRI (up to 1L doses) to develop imaging methods and assess pulmonary function in adults.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperpolarized Xe129</intervention_name>
    <description>During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.</description>
    <arm_group_label>Hyperpolarized 129Xe</arm_group_label>
    <other_name>HP Xenon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy Volunteers:&#xD;
&#xD;
          -  Subject has no diagnosed pulmonary conditions&#xD;
&#xD;
          -  Ability to read and understand English or Spanish&#xD;
&#xD;
        Subjects with Lung Disease:&#xD;
&#xD;
          -  Subject has a diagnosis of pulmonary dysfunction made by a physician&#xD;
&#xD;
          -  No acute worsening of pulmonary function in the past 30 days&#xD;
&#xD;
          -  Ability to read and understand English or Spanish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MRI is contraindicated based on responses to MRI screening questionnaire&#xD;
&#xD;
          -  Subject is pregnant or lactating&#xD;
&#xD;
          -  Subject does not fit into 129Xe vest coil used for MRI&#xD;
&#xD;
          -  Subject cannot hold his/her breath for 15-16 seconds&#xD;
&#xD;
          -  Subject deemed unlikely to be able to comply with instructions during imaging&#xD;
&#xD;
          -  Oxygen saturation &lt;88% on room air or with supplemental oxygen&#xD;
&#xD;
          -  Cognitive deficits that preclude ability to provide consent&#xD;
&#xD;
          -  Institutionalization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Niedbalski, Ph.D.</last_name>
    <phone>913-588-2271</phone>
    <email>pniedbalski@kumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mario Castro, MD</last_name>
    <phone>9135887529</phone>
    <email>mcastro2@kumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter J Niedbalski, PhD</last_name>
      <phone>913-588-2271</phone>
      <email>pniedbalski@kumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 31, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Mario Castro, MD, MPH</investigator_full_name>
    <investigator_title>Division Chief, Pulmonary, Critical Care and Sleep Medicine</investigator_title>
  </responsible_party>
  <keyword>Hyperpolarized 129Xe MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

